DENTSPLY SIRONA Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. DENTSPLY SIRONA Inc. is a global manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company is currently navigating significant headwinds including global trade tariffs, competitive pressures, and the suspension of sales for its Byte aligner business.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $904 | $951 | $2,719 | $2,888 |
| Gross Profit | $441 | $495 | $1,397 | $1,512 |
| Gross Margin | 48.8% | 52.1% | 51.4% | 52.4% |
| Operating Loss | $(218) | $(462) | $(283) | $(370) |
| Net Loss (Attributable to Dentsply Sirona) | $(427) | $(494) | $(452) | $(480) |
| Diluted Loss Per Share | $(2.14) | $(2.46) | $(2.27) | $(2.35) |
| Cash and Cash Equivalents | $363 | $296 | $363 | $296 |
| Total Debt (Current + Long-term) | $2,395 | $2,135 | $2,395 | $2,135 |
| Net Debt to Capitalization | 57.9% | 48.9% | 57.9% | 48.9% |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5.0% in Q3 and 5.9% for the nine months ended September 30, 2025, compared to the prior year. On a constant currency basis, the decline was 8.0% (Q3) and 6.4% (9M).
- Orthodontic and Implant Solutions: Sales dropped 15.0% (Q3) and 17.8% (9M) primarily due to the suspension of Byte aligner sales and lower implant volumes.
- United States: Sales fell 22.2% (Q3) and 18.6% (9M) driven by Byte suspension and lower CAD/CAM and imaging equipment volumes.
- Wellspect Healthcare: Sales increased 15.6% (Q3) and 6.5% (9M) due to new product launches.
- Impairment Charges: The company recorded significant non-cash impairment charges.
- Q3 2025: $262 million total ($253 million goodwill, $9 million intangibles).
- 9M 2025: $497 million total ($409 million goodwill, $88 million intangibles).
- Drivers: Impairments were driven by lower-than-expected volumes, competitive pressures, and the impact of tariffs on the Implant & Prosthetic Solutions reporting unit.
- Operating Expenses: SG&A expenses decreased 8.8% (Q3) and 12.3% (9M) due to lower marketing spend (specifically for Byte) and restructuring cost savings. R&D expenses decreased 9.2% (Q3) and 10.9% (9M).
- Debt Structure: In June 2025, the company issued $550 million of Junior Subordinated Notes due 2055 to repay a $435 million bridge loan and fund general corporate purposes. Total debt increased from $2.135 billion (Dec 2024) to $2.395 billion (Sep 2025).
Guidance, Outlook, and Risks
- Restructuring Plans: The company is executing a 2024 Plan (approved July 2024) targeting a 2-4% global workforce reduction and $80-$100 million in annual cost savings, expected to be substantially completed by end of 2025. A prior 2023 Plan has substantially met its $200 million annual savings target.
- Tariff and Trade Risks: New U.S. tariffs (baseline 10%, 15% on EU goods) and retaliatory measures are increasing costs and impacting demand. The company is evaluating sourcing options and pricing strategies to mitigate these effects.
- Geopolitical Risks: Operations in Israel remain open but face trade restrictions from Turkey. Cash repatriation from Russia is limited due to currency controls and banking restrictions.
- Legal Proceedings:
- Securities Litigation: A class action regarding revenue recognition (distributor rebates) was certified in July 2025. The company has accrued a liability with an offsetting insurance receivable.
- SEC Investigation: Concluded in October 2025 with no enforcement action recommended.
- Merger Litigation: A 2018 class action regarding the Sirona merger was settled for $84 million (approved September 2025), with $78 million covered by insurance.
- Future Impairment Risk: Management warns that further declines in revenue, margins, or increases in discount rates could trigger additional material impairment charges, particularly in the Implant & Prosthetic Solutions and Connected Technology Solutions segments.
Investor Verification Checklist
- Byte Aligner Suspension: Verify the timeline and strategic rationale for the suspension of Byte sales and its long-term impact on the Orthodontic segment.
- Tariff Mitigation: Assess the effectiveness of the company's strategies to offset tariff costs and whether pricing power is being maintained in key markets.
- Impairment Sensitivity: Review the assumptions used in the discounted cash flow models (discount rates, growth rates) for the Implant & Prosthetic Solutions unit to gauge the risk of future write-downs.
- Debt Covenants: Confirm continued compliance with the amended debt covenants (Senior Debt to Capitalization ratio not to exceed 0.6) given the recent increase in leverage.
- Working Capital Trends: Monitor the increase in Days Sales Outstanding (64 days vs 55 days) and Days Sales in Inventory (145 days vs 124 days) for potential cash flow constraints.